A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Trial details
- Registry ID
- NCT05002127
- Drugs studied
- Evorpacept (ALX148), Paclitaxel, Ramucirumab, Trastuzumab
TrialRedline tracks 4 clinical trials sponsored by ALX Oncology Inc.: 1 Phase 2 / 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)NCT05002127 | Evorpacept (ALX148), Paclitaxel, Ramucirumab, Trastuzumab | Completed | 2024-05-24Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559 | Capecitabine, Eribulin, Evorpacept (ALX148), Gemcitabine and 3 more | Recruiting | 2027-12Estimated |
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)NCT04675294 | evorpacept, pembrolizumab | Active not recruiting | 2025-03-03Actual |
| Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)NCT04675333 | Cisplatin/Carboplatin; 5FU, evorpacept, pembrolizumab | Active not recruiting | 2025-03-03Actual |
Names as written in the registry records.
NCT05002127 · ALX Oncology Inc.
Before: Active not recruiting. After: Completed.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: MBC substudy: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment. After: Measure: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment.
Before: 80 participants (planned). After: 120 participants (planned).
Before: Jun 2027. After: Dec 2027.
Before: PHASE1, PHASE2. After: PHASE2.